Full-Time

Care Partner

Updated on 9/3/2026

Dyne Therapeutics

Dyne Therapeutics

201-500 employees

Develops muscle-disease therapies using FORCE platform

Compensation Overview

$190k - $225k/yr

Indianapolis, IN, USA

Remote

Candidates must reside in the assigned territory, live within driving distance of a major commercial airport, and travel up to 50–80%.

Bachelor's

Category
Social & Community Services (2)
,
Required Skills
Care Coordination
Patient Education

Get referred to Dyne Therapeutics

See people who can refer or advise you

Requirements
  • At least 8 years of healthcare or related experience, including at least 5 years of directly relevant experience in patient services, reimbursement, case management, field education, specialty pharmacy, or care coordination.
  • Working knowledge of payer coverage, reimbursement pathways, and access processes, including prior authorizations, appeals, and denials.
  • Ability to build relationships across patients, caregivers, healthcare providers, and cross-functional teams.
  • Strong communication, organizational, and problem-solving skills.
  • Ability to work independently in a field-based environment.
  • Ability to operate effectively in a dynamic environment requiring responsiveness and adaptability.
  • Ability to travel extensively within the assigned geography, up to 50–80%.
  • Flexibility to support patient and provider needs outside standard business hours, including evenings, weekends, and holidays as required.
  • Ability to respond to time-sensitive patient access and treatment coordination needs in a compliant and professional manner.
  • Demonstrated accountability and sound judgment in managing urgent or complex patient situations.
  • Ability to maintain a patient-first mindset during critical treatment milestones, including therapy initiation, infusion scheduling, access challenges, and treatment interruptions.
Responsibilities
  • Serve as a primary point of contact for patients and caregivers throughout the treatment journey.
  • Provide individualized education on disease state, therapy, and treatment expectations using approved materials.
  • Conduct proactive outreach to identify support needs and address access or adherence barriers.
  • Coordinate support services and resources to assist patients and caregivers.
  • Educate patients and caregivers on proper product storage, handling, and administration.
  • Provide education on reimbursement processes to patients, caregivers, healthcare providers, and infusion centers.
  • Support understanding of prior authorizations, appeals, denials, reauthorizations, and site-of-care requirements.
  • Identify reimbursement and access challenges and facilitate appropriate escalation through approved channels.
  • Support continuity of care during insurance changes, site-of-care transitions, and reauthorization events.
  • Build and maintain relationships with healthcare providers, office staff, and infusion partners.
  • Provide education on patient support services, reimbursement processes, and available resources.
  • Support infusion center readiness, including product handling, storage, preparation, and administration requirements.
  • Serve as a reimbursement and access resource within the assigned geography.
  • Partner with HUB services, specialty pharmacies, infusion providers, and internal stakeholders to support patient access and continuity of care.
  • Maintain accurate and timely documentation in approved systems.
  • Ensure compliance with all regulatory, privacy, and company requirements.
  • Identify and appropriately report adverse events, product complaints, and privacy incidents.
Desired Qualifications
  • Bachelor’s degree in nursing, social work, or a related healthcare field.
  • RN, Social Worker, or equivalent healthcare experience.
  • Experience supporting specialty, rare disease, or infused/provider-administered therapies.

Dyne Therapeutics develops therapies for serious muscle diseases using its FORCE™ platform, which helps deliver oligonucleotide medicines to muscle tissue. Through a portfolio of experimental therapies, the company advances them in clinical trials (ACHIEVE and DELIVER) with the aim of treating rare muscle diseases. The product works by enhancing targeted delivery of oligonucleotides to muscle, enabling existing genetic medicines to reach affected tissues more effectively. Dyne differentiates itself by its proprietary FORCE™ technology and its focus on rare muscle diseases, positioning itself for growth as trials progress toward potential commercialization. The company’s goal is to bring effective treatments to patients and families affected by serious muscle diseases, expanding options as its therapies advance through development and, potentially, regulatory approval.

Company Size

201-500

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2017

Get referred to Dyne Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Dyne ended June 30, 2026 with $898.5 million cash and July equity proceeds.
  • ACHIEVE enrolled 71 participants in June 2026; HARMONIA dosing began July 2026.
  • FDA granted Priority Review for z-rostudirsen July 20, 2026, signaling regulatory momentum.

What critics are saying

  • Sarepta's Exondys 51 and gene-therapy franchise defend exon-51 patients before January 2027.
  • If z-rostudirsen misses approval, Dyne stays pre-revenue and financing resets by 2028.
  • June 30, 2026 net loss hit $178.6 million, pressuring execution across three programs.

What makes Dyne Therapeutics unique

  • FORCE™ targets muscle delivery, pairing oligonucleotides with tissue-specific uptake, not broad systemic exposure.
  • Zeleciment rostudirsen's January 21, 2027 PDUFA is first-in-class commercialization for Dyne.
  • Dyne spans DMD, DM1, and FSHD, creating multiple shots on muscle-disease biology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

-1%
Yahoo Finance
Sep 8th, 2026
Dyne Therapeutics shares plunge 31% premarket with no confirmed catalyst

Dyne Therapeutics shares dropped 31% to $16.76 in premarket trading on Tuesday, with no official company announcement explaining the decline. The biotechnology firm is developing treatments for neuromuscular diseases, including z-rostudirsen for Duchenne muscular dystrophy, which has a regulatory decision date of 21 January 2027. The company recently reported a quarterly net loss of $178.6 million, or $1.08 per share, missing consensus estimates of $0.75 per share. The sharp decline stood in contrast to broader market moves, with the S&P 500 down 0.3% and the Nasdaq slipping 0.1% during the same period. No new clinical or regulatory developments were confirmed to explain the trading movement.

Central Charts
Jul 21st, 2026
Dyne Therapeutics launches $300M public stock offering for neuromuscular disease therapies

Dyne Therapeutics has commenced an underwritten public offering of $300 million of its common stock. The clinical-stage company, which focuses on treatments for genetically driven neuromuscular diseases, also plans to grant underwriters a 30-day option to purchase up to an additional $45 million of shares. Morgan Stanley, Jefferies and Evercore ISI are acting as joint book-running managers for the offering. LifeSci Capital and Raymond James are also serving as joint book-running managers, whilst Jones is acting as lead manager. The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission on 5 March 2024. The company is currently developing clinical programmes for myotonic dystrophy type 1 and Duchenne muscular dystrophy.

BioSpace
Jul 21st, 2026
Dyne gets early 2027 decision date for Duchenne therapy, analysts expect 'smooth' review.

Dyne gets early 2027 decision date for Duchenne therapy, analysts expect 'smooth' review. July 21, 2026 | If approved, Dyne Therapeutics' zeleciment rostudirsen could "capture the majority" of the exon-51 Duchenne muscular dystrophy market, given its better efficacy and dosing profile versus Sarepta Therapeutics' exon-skipping therapy Exondys 51, the current standard of care, according to Oppenheimer. The FDA has accepted Dyne Therapeutics' application for its investigational Duchenne muscular dystrophy therapy, setting a target action date of Jan. 21, 2027. "We anticipate a smooth approval," Oppenheimer told investors in a note on Monday, adding that the therapy, dubbed zeleciment rostudirsen (z-rostudirsen) is poised to "capture the majority of market share," given stronger dystrophin benefits and a more convenient dosing profile than the current standard treatment. Outside of symptomatic management through corticosteroids, Sarepta Therapeutics' Exondys 51 is a standard of care regimen for patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping. Dyne, however, could challenge Exondys with z-rostudirsen, which in the Phase 1/2 DELIVER trial outperformed Sarepta's asset, Jefferies said in a Monday note, adding that the early data cut looks "best-in-class." Exondys is dosed weekly, while z-rostudirsen is designed to be given once every four weeks - a "convenient" profile, the firm noted. Given its convenience and efficacy advantages, "z-rostudirsen could command a pricing premium" if approved, Jefferies continued. The analysts added that they expect uptake to be "robust" across three key patient subgroups: those who have yet to undergo Exondys treatment, those who have discontinued Sarepta's therapy and those who are currently receiving it. Dyne is seeking accelerated approval for z-rostudirsen in patients with DMD who are amenable to exon 51 skipping, according to a company release on Monday. Topline data from the registrational cohort of DELIVER, released December 2025, showed a 5.46% increase at six months in concentrations of the dystrophin protein, a key disease marker. Patients also saw improvements in key functional measures, including time-to-rise velocity and the 10-meter walk/run test. Lung function, a major driver of death in DMD, was preserved at six months. Dyne's exon-skipping therapy zeleciment rostudirsen resulted in an approximately sevenfold increase in dystrophin levels at six months and elicited functional improvements that are the "best ever" for this treatment class, Stifel analysts said. December 8, 2025 The FDA does not plan on holding an advisory committee meeting for z-rostudirsen, according to Dyne. Jefferies models more than $500 million in peak sales for z-rostudirsen, calling this estimate "conservative." Oppenheimer, on the other hand, did not provide a peak forecast for the z-rostudirsen, only noting that Dyne's therapy could secure a "majority" of the $1.5 billion exon-51 DMD market. In DMD, a rare and progressive neuromuscular disorder, mutations to the dystrophin protein render it dysfunctional or completely absent. Under healthy conditions, dystrophin plays a crucial role in maintaining the structure and function of muscles. Z-rostudirsen works by restoring the expression of near-full-length dystrophin, in turn restoring the function of the protein. A key player in the DMD space is Sarepta, which aside from Exondys owns the gene therapy Elevidys. Last year, two patients died after receiving Elevidys, which ultimately forced the FDA to slap a boxed warning on the product's label and limited its use to ambulatory patients four years and up. Sarepta also owns Amondys 45 and Vyondys 53 - both exon-skipping drugs like Exondys - which in November 2025 failed to elicit significant motor function improvements in the confirmatory Phase 3 ESSENCE study. Sarepta has nevertheless pushed for full approval of these products, with the FDA setting a decision date of Feb. 28, 2027. Sarepta Therapeutics is seeking to convert the accelerated approval of its therapeutic exon-skippers for Duchenne muscular dystrophy to full despite the drugs' failure to improve motor function in a confirmatory trial. July 1, 2026

Quiver Quantitative
Jul 21st, 2026
Dyne Therapeutics Announces $300 Million Proposed Public Offering of Common Stock

Dyne Therapeutics announces a $300 million public offering of common stock to support its neuromuscular disease programs.Quiver AI SummaryDyne Therapeutics, Inc. has announced the commencement of an underwritten public offering of $300 million in shares of its common stock, with a potential additional sale of $45 million if underwriters exercise their option. The shares will be sold by Dyne, and the offering is being managed by Morgan Stanley, Je

Nasdaq
Jul 3rd, 2026
Dyne Therapeutics Closes $230 Million Public Offering of Common Stock

Dyne Therapeutics completes $230 million public offering of 27.8 million shares to advance neuromuscular disease therapies. |